Mirus Bio LLC

Mirus Bio LLC is a life science company focused on discovering, developing and commercializing innovative nucleic acid based technologies and products. Mirus R&D uniquely integrates nucleic acid delivery and chemistry, a core competency which is unmatched in the industry. This serves as the foundation for its novel research reagents. Mirus is a recognized leader in developing innovative nucleic acid research reagents, distinguished by its many accomplishments: ■First to develop an siRNA transfection reagent (2001) ■Pioneered development of high efficiency/low toxicity transfection formulations ■First to market a single step nucleic acid labeling technology ■Unique technology to label native, biologically relevant short RNA species such as microRNA Mirus’ TransIT® Reagents are unique lipid and polymer formulations that achieve superior delivery efficiency of pDNA and siRNA with minimal cytotoxic effects. They have been optimized for in vitro delivery in a variety of mammalian cells as well as for in vivo delivery in small animals. The Ingenio™ Electroporation Solution allows researchers to deliver nucleic acids to cells that are resistant to transfections. The company’s Label IT® Kits employ proprietary chemistry to covalently attach labeling molecules to DNA and RNA. This simple one-step process is faster and more robust than traditional multi-step enzymatic labeling, and can be used for intracellular tracking, chromosome analysis, and microarray labeling.